- Martin Bashir resigns from MSNBC over ‘ill-judged’ comments about Sarah Palin
- Rep. Duncan Hunter: While Obama prays for Iranian change, U.S. should ready its nukes
- Best company ever? Veteran Beer Co. exists to employ vets, provide quality beer
- Iran official: Sanctions ‘utterly failed’ to stop nuclear program
- ‘Black Santa’ display at IU sparks student outrage
- Joint Chiefs chair Dempsey: Pentagon, VA too slow in merging medical systems
- Sen. Ben Cardin hits Ukraine for crackdown on Kiev protests
- Drone technology turns South, targets feral pigs to kill
- Puerto Rico caravan honoring Paul Walker ends in 6 drunken-driving arrests, 72 speeding tickets
- Better pack a lightsaber: House told space explorers could find alien life in 10 years
Daily HIV pill use yields strong results
Can reduce risk of getting virus by 73%
Question of the Day
Men who faithfully take a daily pill that contains drugs to treat HIV can reduce their risk of catching the deadly virus by up to 73 percent, the National Institutes of Health said in a study released Tuesday.
Researchers cautioned, however, that Truvada, an anti-retroviral drug now used by people already infected with HIV, achieves such stunning success only when taken diligently and used in combination with other prevention strategies.
“I am encouraged by this announcement of groundbreaking research on HIV prevention,” President Obama said after the NIH study findings were announced. “While more work is needed, these kinds of studies could mark the beginning of a new era in HIV prevention.”
“These results represent a major advance in HIV prevention research,” said Dr. Kevin Fenton, director of the Centers for Disease Control and Prevention’s (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention.
“For the first time, we have evidence that a daily pill used to treat HIV is partially effective for preventing HIV among gay and bisexual men at high risk for infection, when combined with other prevention strategies,” Dr. Fenton said. This is “exciting and welcome news.”
The approach is called “pre-exposure prophylaxis,” or PREP.
The men were given pills to take daily without knowing whether it was Truvada or a placebo. They were then checked regularly for HIV status, and assessed on how well they adhered to safe-sex strategies and pill regimen.
Some 110 of the men acquired HIV — 64 were taking placebo pills, and 36 were taking Truvada.
Based on this outcome, researchers said, the men who faithfully took the Truvada pills on 90 percent or more days lowered their risk of getting HIV by about 73 percent. In general, the risk reduction for all men was about 44 percent. According to the CDC, though, that the HIV risk for the least-compliant group of men declined by only 21 percent.
Taking the drug also doesn’t seem to encourage risky behavior in response. The NIH study also found that after the men started the study, their risky sexual behavior “decreased substantially” and “remained lower” than usual during the drug trial.
Dr. Fenton cautioned that these results were only for Truvada use in a male homosexual and bisexual populations. There are no data regarding Truvada’s ability to prevent AIDS among heterosexuals, women or intravenous drug users, he said.
It also was effective only with men who were confirmed HIV-negative and who practiced additional prevention strategies such as consistently using condoms, getting treatment for other sexually transmitted diseases and reducing the number of sex partners.
The hope is that high-risk populations — men who have sex with men (MSM) and bisexual men — will use an HIV-prevention pill. Surveys indicate that “the majority” of men in these groups would consider using such a product if it was proved to be safe and effective, the NIH study said.
© Copyright 2013 The Washington Times, LLC. Click here for reprint permission.
About the Author
Cheryl Wetzstein covers family and social issues as a national reporter for The Washington Times. She has been a reporter for three decades, working in New York City and Washington, D.C. Since joining The Washington Times in 1985, she has been a features writer, environmental and consumer affairs reporter, and assistant business editor. Beginning in 1994, Mrs. Wetzstein worked exclusively ...
- Embryonic stem cell research falls out of favor as scientists go ethical
- With new HIV research, FDA may let gay men donate blood
- HHS report shows a decrease in blood supply but also a drop in demand
- Little change in practice for China's one-child family policy
- Gay-marriage momentum comes to a sudden halt after Illinois
Latest Blog Entries
- Pro-life, stem-cell bill signed into law by Kansas Gov. Sam Brownback
- N. Dakota lawmakers approve tough abortion bill
- Pope Benedict XVI's successor should allow priests to get a new title: Husband, poll finds
- House votes to reject Obama welfare shift
- Report: Two out of three Democrats support gay marriage
By Tom Harris and Madhav Khandekar
Bad science puts rich nations on the hook for trillions in climate liabilities
- Hola: Boehner prepares to push amnesty bill through House
- Kill team: Obama war chiefs widen drone death zones
- U.S. drops 2,000 mice on Guam by parachute to kill snakes
- Doctors say profound new HIV treatment may prove the cure
- Inside China: Nuclear submarines capable of widespread attack on U.S.
- EDITORIAL: Motor City meltdown
- CARSON: Getting to the top by starting at the bottom
- Last call: State Dept. bought $180,000 in liquor before shutdown
- MILLER: Obamas EPA closing smelter will not affect ammunition supply
- Obama: Growing income inequality 'defining challenge' of this generation
Independent voices from the The Washington Times Communities
The Career Doctor Cassi Fields prescribes valuable advice for anyone looking to find a career, nail an interview or earn a promotion.
Headlines from Associated Press and around the Internet
Columns from Voices around the World talking about the events, people, politics and social issues that concern us wherever, and whoever, we are.
This column will cover anything that has anything remotely to do with the game of baseball, from the game itself to mid-summer trades to offseason moves.